Matilda Jackson

Dr. Matilda Jackson

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2017 in Diseases
Verified
Journal Article
Open access
PDF file
ADAinslie Derrick-Roberts
Ainslie Derrick-Roberts
MJMatilda Jackson
Matilda Jackson
CPCarmen E. Pyragius
Carmen E. Pyragius
SBSharon Byers
Sharon Byers
Mucopolysaccharidosis type I (MPS I) is the most common form of the MPS group of genetic diseases. MPS I results from a deficiency in the lysosomal enzyme α-l-iduronidase, leading to accumulation of undegraded heparan and dermatan sulphate glycosaminoglycan (GAG) chains in patient cells. MPS children suffer from multiple organ failure and die in their teens to early twenties. In particular, MPS I children also suffer from profound mental retardation and skeletal disease that restricts growth and movement. Neither brain nor skeletal disease is adequately treated by current therapy approaches. To overcome these barriers to effective therapy we have developed and tested a treatment called substrate deprivation therapy (SDT). MPS I knockout mice were treated with weekly intravenous injections of 1 mg/kg rhodamine B for six months to assess the efficacy of SDT. Mice were assessed using biochemistry, micro-CT and a battery of behaviour tests to determine the outcome of treatment. A reduction in female bodyweight gain was observed with the treatment as well as a decrease in lung GAG. Behavioural studies showed slight improvements in inverted grid and significant improvements in learning ability for female MPS I mice treated with rhodamine B. Skeletal disease also improved with a reduction in bone mineral volume observed. Overall, rhodamine B is safe to administer to MPS I knockout mice where it had an effect on improving aspects of neurological and skeletal disease symptoms and may therefore provide a potential therapy or adjunct therapy for MPS I patients.

8 July 2014 in Human Gene Therapy
Verified
Journal Article
Closed access
ADAinslie L.K. Derrick-Roberts
Ainslie L.K. Derrick-Roberts
CPCarmen E. Pyragius
Carmen E. Pyragius
XKXenia M. Kaidonis
Xenia M. Kaidonis
MJMatilda Jackson
Matilda Jackson
DADonald S. Anson
Donald S. Anson
SBSharon Byers
Sharon Byers
A number of mucopolysaccharidosis type VII (MPS VII) mouse models with different levels of residual enzyme activity have been created replicating the range of clinical phenotypes observed in human MPS VII patients. In this study, a lentivirus encoding murine β-glucuronidase was administered intravenously at birth to both the severe (Gus mps/mps strain) and attenuated (Gus tm(L175F)Sly strain) mouse models of MPS VII. Circulating enzyme levels were normalized in the Gus mps/mps mice and were 3.5-fold higher than normal in the Gus tm(L175F)Sly mouse 12 and 18 months after administration. Tissue β-glucuronidase activity increased over untreated levels in all tissues evaluated in both strains at 12 months, and the elevated level was maintained in Gus tm(L175F)Sly tissues at 18 months. These elevated enzyme levels reduced glycosaminoglycan storage in the liver, spleen, kidney, and heart in both models. Bone mineral volume decreased toward normal in both models after 12 months of therapy and after 18 months in the Gus tm(L175F)Sly mouse. Open-field exploration was improved in 18-month-old treated Gus tm(L175F)Sly mice, while spatial learning improved in both 12- and 18-month-old treated Gus tm(L175F)Sly mice. Overall, neonatal administration of lentiviral gene therapy resulted in sustained enzyme expression for up to 18 months in murine models of MPS VII. Significant improvements in biochemistry and enzymology as well as functional improvement of bone and behavior deficits in the Gus tm(L175F)Sly model were observed. Therapy significantly increased the lifespan of Gus mps/mps mice, with 12 months being the longest reported lentiviral treatment for this strain. It is important to assess the long-term outcome on enzyme levels and effect on pathology for lentiviral gene therapy to be a potential therapy for MPS patients.

15 March 2017 in European Journal of Human Genetics
Verified
Journal Article
Closed access
LELisa J Ewans
Lisa J Ewans
MFMichael Field
Michael Field
YZYing Zhu
Ying Zhu
GTGillian Turner
Gillian Turner
MLMelanie Leffler
Melanie Leffler
CSCheryl Shoubridge
Cheryl Shoubridge

1 September 2017 in Neurobiology of Disease
Verified
Journal Article
Closed access
MJMatilda Jackson
Matilda Jackson
KLKristie Lee
Kristie Lee
TMTessa Mattiske
Tessa Mattiske
EJEmily J. Jaehne
Emily J. Jaehne
EOEzgi Ozturk
Ezgi Ozturk
CSCheryl Shoubridge
Cheryl Shoubridge

19 September 2024 in Genetics in Medicine
Verified
Journal Article
Closed access
RRRocio Rius
Rocio Rius
ACAlison G Compton
Alison G Compton
NBNaomi L. Baker
Naomi L. Baker
SBshanti balasubramaniam
shanti balasubramaniam
SBStephanie Best
Stephanie Best
DTDavid R. Thorburn
David R. Thorburn

1 April 2015 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
MJMatilda Jackson
Matilda Jackson
ADAinslie Derrick-Roberts
Ainslie Derrick-Roberts
EMEllenore Martin
Ellenore Martin
NRNathan Rout-Pitt
Nathan Rout-Pitt
SGStan Gronthos
Stan Gronthos
SBSharon Byers
Sharon Byers